AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28012280
Drug: Milk fat
RxNorm normalized name: MILK FAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk fat low in MC-SFA (63 g/day)
Trial: 26296511
Drug: Perampanel (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel (up titrated from 2 to 8 mg/d, or highest tolerated dose)
Trial: 14661567
Drug: Nicorandil (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (2 mg bolus injection 3 minutes before propofol injection, followed by continuous infusion at 6 mg.h‐1)
Trial: 8720807
Drug: Furosemide suppositories
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide suppositories
Trial: 8720807
Drug: Furosemide sodium
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide sodium suppositories
Trial: 7427858
Drug: Adriamycin (ADR),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adriamycin (ADR), 60 mg/M2 I.V. q three weeks
Trial: 7427858
Drug: Methotrexate (MTX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (MTX), 40 mg/M2 I.V. q one week
Trial: 7427858
Drug: 5-fluorouracil (5-FU),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil (5-FU), 500 mg/m2 I.V. x 5 days q five weeks
Trial: 27974712
Drug: Sofosbuvir (SOF)
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir (SOF) and Ledipasvir (LDV) therapy
Trial: 17030169
Drug: VX-950 450
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VX-950 450 mg every 8 hours
Trial: 17030169
Drug: VX-950 750
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VX-950 750 mg every 8 hours
Trial: 17030169
Drug: VX-950 1250
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VX-950 1250 mg every 12 hours
Trial: 17030169
Drug: VX-950 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VX-950 (all doses)
Trial: 10672977
Drug: labetalol 200
RxNorm normalized name: HCTZ 25/LABETALOL 200MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: labetalol 200 mg
Trial: 7962893
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy (GT)
Trial: 2888813
Drug: Flucloxacillin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flucloxacillin (1 mg l-1)
Trial: 2888813
Drug: Tobramycin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin (2 mg l-1)
Trial: 24943105
Drug: PEG 4000
RxNorm normalized name: PEG 4000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG 4000 (8 g per day)
Trial: 24943105
Drug: Lactulose (3.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (3.3 g per day)
Trial: 17617747
Drug: Ranolazine 1000
RxNorm normalized name: ranolazine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine 1000 mg bid
Trial: 20828645
Drug: Ranolazine 1500
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranolazine 1500 mg bid
Trial: 10389680
Drug: Tramadol (840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (840 mg, range: 80-1920 mg)
Trial: 10389680
Drug: Morphine (238
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (238 mg, range: 20-1125 mg)
Trial: 3890986
Drug: PPSB (prothrombin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPSB (prothrombin complex preparation)
Trial: 26394360
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron treatment (80 mg/day for 4 weeks)
Trial: 24868583
Drug: 0.12% topical
RxNorm normalized name: Luxiq 0.12% Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% topical unoprostone twice daily in a randomly selected eye
Trial: 20178625
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium vegetable juice (8 or 16 fluid ounces daily)
Trial: 12586793
Drug: Doxorubicin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60 mg/m(2))
Trial: 12586793
Drug: Paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg/m(2)/24 h)
Trial: 12586793
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of doxorubicin and paclitaxel (AT, 50 mg/m(2) and 150 mg/m(2)/24 h, plus granulocyte colony‐stimulating factor 5 mg/kg)
Trial: 12586793
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of doxorubicin and paclitaxel (AT)
Trial: 10028207
Drug: Weekly calendar
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly calendar reports
Trial: 8694157
Drug: Tenoxicam 20
RxNorm normalized name: tenoxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 20 mg added to prilocaine in a standard Bier's block (group 2)
Trial: 7061773
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group (HDG) received a mean cumulative dose of 3440 microgram cat allergen 1 (cat 1) and 10,660 microgram cat albumin (alb).
Trial: 7061773
Drug: Intermediate-dose group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-dose group (IDG) received 70 microgram cat 1 and 217 microgram alb.
Trial: 7061773
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group (LDG) received 0.930 microgram cat 1 and 2.86 microgram alb.
Trial: 27247174
Drug: Life Goals‐Collaborative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Life Goals‐Collaborative Care (LG‐CC)
Trial: 18803940
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 1000 mg/d
Trial: 12165641
Drug: Adjuvant 5-fluorouracil-based
RxNorm normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant 5-fluorouracil-based chemotherapy
Trial: 2624617
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion in potassium-depleted subjects
Trial: 31559589
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D supplementation (300,000 IU for deficiency, 150,000 IU for insufficiency) administered orally 48 hours before CABG surgery
Trial: 18781066
Drug: 2% starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% starch gel-like solution
Trial: 18781066
Drug: 2% starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% starch and 10% sucrose solution
Trial: 18781066
Drug: 2% starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% starch solution followed by 10% sucrose solution
Trial: 11069341
Drug: Subcutaneous tunnelling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous tunnelling with a loop for epidural catheter fixation (n = 34)
Trial: 1567042
Drug: Promethazine (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine (0.625 mg/PCA dose, average of 17.6 mg/24 h)
Trial: 1567042
Drug: Control (PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (PCA with morphine only, 1.5 mg, 6-min lockout interval)
Trial: 3901826
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) 650 mg daily postoperatively
Trial: 3901826
Drug: No aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aspirin (NASA)
Trial: 30515560
Drug: SwallowIT-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SwallowIT-assisted therapy (n=26)
Trial: 30515560
Drug: Clinician-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician-directed therapy (n=26)
Trial: 30515560
Drug: Patient-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-directed therapy (n=27)
Trial: 29696707
Drug: vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitamin D3 (5000 IU daily) + phenylbutyrate (2 × 500 mg daily)
Trial: 22524447
Drug: Cisatracurium besylate
RxNorm normalized name: Cisatracurium Besylate
DrugBank: Cisatracurium (DB00565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisatracurium besylate therapy within 2 days of ARDS onset
Trial: 18366490
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of misoprostol (400 microg three‐hourly, up to a maximum of five doses over 24 h)
Trial: 18366490
Drug: Vaginal administration
RxNorm normalized name: Antiinflammatory products for vaginal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration of misoprostol (400 microg three‐hourly, up to a maximum of five doses over 24 h)
Trial: 18366490
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of misoprostol
Trial: 18366490
Drug: Vaginal administration
RxNorm normalized name: Antiinflammatory products for vaginal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration of misoprostol
Trial: 11873073
Drug: Protease inhibitor-containing
RxNorm normalized name: Protease inhibitor-containing product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor-containing regimen (group 2; 49 patients)
Trial: 10202784
Drug: Induction chemotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy, allogeneic or autologous bone marrow transplantation (BMT)
Trial: 7586246
Drug: Streptokinase/subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase/subcutaneous heparin therapy
Trial: 1430679
Drug: Combination thrombolytic
RxNorm normalized name: THROMBOLYTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination thrombolytic therapy
Trial: 2154430
Drug: Azithromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (250 mg bd on day 1 and 250 mg once daily on days 2-5)
Trial: 2154430
Drug: Erythromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (500 mg every 6 h for seven days)
Trial: 2154430
Drug: Azithromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1 g single dose or 500 mg single dose on day 1 and 250 mg once daily on days 2 and 3)
Trial: 2154430
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg every 12 h for seven days)
Trial: 426993
Drug: Pancuronium 0.02‐0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.02‐0.08 mg kg‐1
Trial: 426993
Drug: Fentanyl 0.003
RxNorm normalized name: fentanyl 0.003 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 0.003 mg kg‐1 plus droperidol 0.15 mg kg‐1
Trial: 426993
Drug: Fentanyl 0.003
RxNorm normalized name: fentanyl 0.003 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 0.003 mg kg‐1
Trial: 23517287
Drug: pegylated‐IFNα2a weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegylated‐IFNα2a weekly or albumin‐IFNα2b every 2 weeks for up to 24 weeks
Trial: 16287396
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy for Sexual Abuse Survivors (CPT‐SA)
Trial: 8788692
Drug: Day treatment
RxNorm normalized name: Pharmacist Clotrimazole 3 Day Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day treatment (intensive seven-day-a-week neurobehavioral treatment model program)
Trial: 8788692
Drug: Traditional outpatient
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional outpatient treatment (conventional five-day-a-week program)
Trial: 2405746
Drug: Inhaled pirbuterol
RxNorm normalized name: pirbuterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled pirbuterol
Trial: 155297
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of beta 2-sympathomimetic (salbutamol or fenoterol) and SCH 1000
Trial: 29235507
Drug: Liraglutide (GLP-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (GLP-1 analog), 6 months treatment
Trial: 23886886
Drug: Action Observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Action Observation Therapy (AOT) - observing video sequences of unimanual or bimanual goal-directed actions for 1 hour per day for 3 weeks followed by execution of observed actions
Trial: 21402628
Drug: 24% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24% sucrose solution orally
Trial: 21402628
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of liposomal lidocaine cream topically
Trial: 19359148
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (12.3 mmol or 300 mg of elemental magnesium in the form of magnesium oxide, n=75)
Trial: 17349076
Drug: Meat-containing meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meat-containing meal with mustard (3 g)
Trial: 17349076
Drug: Non meat-containing
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non meat-containing meal with mustard (3 g)
Trial: 10356434
Drug: Experience with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experience with dental injections
Trial: 7989975
Drug: Radioiodine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine therapy (0.85‐9.55 GBq or 23‐258 mCi of 131I)
Trial: 2670220
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (captopril, enalapril, quinapril)
Trial: 28719834
Drug: After one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After one year of GH therapy
Trial: 25150178
Drug: Bosentan treatment
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan treatment for 12 weeks
Trial: 18327133
Drug: Vitrectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitrectomy with ILM peeling followed by IVTA injection
Trial: 7977090
Drug: Felodipine, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine, 5 mg once daily
Trial: 7977090
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate (ISMN), 20 mg twice daily
Trial: 3197098
Drug: Dihydroergotamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine (10 mg) + Acetylsalicylic acid (80 mg)
Trial: 29468817
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL regular coffee containing 34.8 μmol nicotinic acid (NA) and 0.58 μmol nicotinamide (NAM)
Trial: 25834948
Drug: 10-mg idursulfase-IT
RxNorm normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10-mg idursulfase-IT
Trial: 25834948
Drug: 30-mg idursulfase-IT
RxNorm normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 30-mg idursulfase-IT
Trial: 25834948
Drug: 1-mg idursulfase-IT
RxNorm normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1-mg idursulfase-IT
Trial: 19892540
Drug: Tiotropium 18μg
RxNorm normalized name: tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18μg inhalation capsules once daily
Trial: 19892540
Drug: Placebo inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation capsules once daily
Trial: 18375477
Drug: Plasma butyrylcholinesterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma butyrylcholinesterase (BuChE) activity <600 mU/ml in chlorpyrifos poisoning
Trial: 18375477
Drug: Plasma butyrylcholinesterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma butyrylcholinesterase (BuChE) activity <600 mU/ml in dimethoate poisoning
Trial: 11430713
Drug: Group motor
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group motor skill intervention, once weekly for 10 weeks
Trial: 9566656
Drug: Melatonin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin treatment (2.5 to 7.5 mg based on body weight)
Trial: 8110567
Drug: 1% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% ropivacaine 10 ml
Trial: 8110567
Drug: 0.5% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ropivacaine 20 ml
Trial: 8110567
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine 20 ml
Trial: 27352003
Drug: Dexmedetomidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (50 μg kg−1) and midazolam (0.45 mg kg−1)
Trial: 27352003
Drug: Dexmedetomidine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (30 μg kg−1), midazolam (0.45 mg kg−1) and butorphanol (0.25 mg kg−1)
Trial: 15677411
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (CBT) + Diet for 6 weeks
Trial: 15677411
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (CBT) + Diet
Trial: 11350261
Drug: MCT (medium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCT (medium chain triglycerides) 15 mL h(‐1)
Trial: 11350261
Drug: MCT (medium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCT (medium chain triglycerides) 30 mL h(‐1)
Trial: 7639370
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of 25 mL of 0.75% bupivacaine
Trial: 7639370
Drug: Staged injection
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staged injection of 25 mL of 0.75% bupivacaine
Trial: 20473734
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with Jinlong Capsule (JLC) and transcatheter arterial chemoembolization (TACE)
Trial: 12728024
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (posterior or anterior arthrodesis and instrumentation)
Trial: 12728024
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (application of a body cast or orthosis)
Trial: 8772681
Drug: c7E3 Fab
RxNorm normalized name: aDabi-Fab
DrugBank: Idarucizumab (DB09264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: c7E3 Fab (antiplatelet IIb/IIIa receptor antibody)
Trial: 29458237
Drug: Irinotecan (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (80 mg/m2, days 1 and 8) plus capecitabine (1,000 mg/m2 twice a day, days 1-14)
Trial: 29458237
Drug: Capecitabine alone
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine alone (1,250 mg/m2 twice a day, days 1-14)
Trial: 29393675
Drug: Dual-hormone artificial
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dual-hormone artificial pancreas (hypoglycemia awareness)
Trial: 29393675
Drug: Single-hormone artificial
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-hormone artificial pancreas (hypoglycemia awareness)
Trial: 26741052
Drug: Topical naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical naltrexone (1 drop, 4 drops) at dosages of 1 × 10(‐6) M, 5 × 10(‐6) M, 1 × 10(‐5) M, 5 × 10(‐5) M
Trial: 25005652
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (varenicline + nicotine patch)
Trial: 23270509
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care and standard care
Trial: 21062129
Drug: Mebendazole (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole (500 mg) plus Ivermectin (200 μg/kg)
Trial: 21062129
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg) plus Ivermectin (200 μg/kg)
Trial: 21062129
Drug: Mebendazole (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole (500 mg) plus placebo
Trial: 21062129
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg) plus placebo
Trial: 28369530
Drug: Ivermectin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (200 μg/kg)
Trial: 19633577
Drug: Balsalazide 6.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balsalazide 6.75 g/day